Shanghai Kaibao Pharmaceutical (300039) Fundamentals 2026 — P/E 23.3x, Revenue Analysis | SniperIQ
Shanghai Kaibao Pharmaceutical (300039) is a CN-listed Healthcare company in Drug Manufacturers - Specialty & Generic with a market capitalization of ¥6.0B, trading at ¥5.76 on the SHZ. This SniperIQ fundamentals page covers Shanghai Kaibao Pharmaceutical's valuation (P/E 23.3x, P/B 1.3x), profitability (net margin 25.0%), revenue (¥1.2B in FY2025), balance-sheet quality, and AI signal context — from live market data, research only.
Full research coverage
- 8-Quarter Revenue & Margin Trend
- Debt Maturity & Coverage
- Peer Valuation Comparison
- Free Cash Flow & Owner Earnings
- AI Signal + Institutional Flow
- DCF Valuation Model
Frequently Asked Questions
What is Shanghai Kaibao Pharmaceutical's market cap?
Shanghai Kaibao Pharmaceutical (300039) has a market capitalization of approximately ¥6.0B, trading at ¥5.76 on the SHZ. Market cap moves with the live share price.
What is Shanghai Kaibao Pharmaceutical's P/E ratio?
Shanghai Kaibao Pharmaceutical's trailing twelve-month P/E ratio is 23.3x, with a price-to-book (P/B) of 1.3x. Valuation multiples are best compared with Healthcare sector peers rather than read in isolation.
How profitable is Shanghai Kaibao Pharmaceutical?
Shanghai Kaibao Pharmaceutical runs a net profit margin of 25.0%, a gross margin of 80.3%, and an operating margin of 28.9%. Margins and ROE indicate how efficiently the business converts sales into profit and shareholder returns.
How much revenue does Shanghai Kaibao Pharmaceutical generate?
Shanghai Kaibao Pharmaceutical reported revenue of ¥1.2B for fiscal year 2025, with net income of ¥279M and earnings per share (EPS) of 0.27. SniperIQ tracks the full 8-quarter revenue and margin trend on the research dashboard.
Does Shanghai Kaibao Pharmaceutical pay a dividend?
Shanghai Kaibao Pharmaceutical offers a trailing dividend yield of about 2.3%. Dividend sustainability depends on payout ratio, free cash flow, and earnings stability — all tracked in SniperIQ's fundamentals view.
Is Shanghai Kaibao Pharmaceutical financially healthy?
Shanghai Kaibao Pharmaceutical carries a debt-to-equity ratio of 0.00x and a current ratio of 11.09x, with a market beta of 0.27. Lower leverage and a current ratio above 1.0 generally signal a stronger balance sheet.
Is Shanghai Kaibao Pharmaceutical a good stock to buy in 2026?
SniperIQ provides research-only market intelligence, not personalised financial advice or a buy/sell call. For Shanghai Kaibao Pharmaceutical (300039) the key facts are: market cap ¥6.0B, P/E 23.3x, revenue ¥1.2B, 52-week range 4.02-7.03. Weigh valuation, profitability, growth, and balance-sheet strength against Healthcare peers and form your own view.
Track Shanghai Kaibao Pharmaceutical's full fundamentals live
Get Shanghai Kaibao Pharmaceutical's 8-quarter revenue and margin trend, peer comparison, DCF model, and AI signal on the SniperIQ research dashboard.